Heart failure drug forecast and marke t industry riding on regulatory and change in consumer prefe

Heart Failure Drug Forecast and Marke tIndustry Riding on Regulatory and Change in Consumer Preferences Published on : 05 March 2020

Report Overview Heart failure( HF) is a clinical syndrome where the heart is unable to meet the demands of the body with a sufficient blood supply. This can be due to structural or functional cardiac abnormalities which can be caused by unexpected injury such as myocardial infarction, or an underlying pathogenesis such as hypertension (Krum and Abraham, 2009). The heart then begins to employ compensatory mechanisms that soon become maladaptive - Frank-Starling mechanism, neurohormonal activation and ventricular remodeling. All of which help to relieve stress initially but long term, cause strain on the cardiac muscle and inevitably progression of HF. HF is a global healthcare concern and affected patients suffer from poor quality of life and poor prognosis. Risk factors for HF include; diabetes, hypertension and obesity, all of which are on the rise in the current population. There is a large unmet need in HF for a treatment option that meets clinical end points in reduced mortality and hospitalization.

Key Highlights : • The main driver of the HF market expansion will be the approval and launch of the SGLT inhibitors for both HF-REF and HF-PEF. • Another prominent contributor to sales growth will be the approval of the large number of pipeline therapies across the 8MM. • The major global barrier for the HF market will be the annual cost of therapy for new pipeline drugs compared to the standard of care generics, alongside the unwillingness for prescribers to add new drugs to large therapy regimens.

Key Questions Answered • SGLT inhibitors will enter the market and see a significant uptake in patient shares for the treatment of HF. However, there are high unmet needs within the indication. What are the main unmet needs in this market?

Will the drugs under development fulfill the unmet needs of the HF market?

• - The current late-stage HF pipeline consists of chronic therapies such as Farxiga and Jardiance, post-acute therapies such as omecamtiv mecarbil and Zynquista, and acute therapies such as istaroxime. Will the latestage drugs make a significant impact on the HF market? Which of these drugs will have the highest peak sales at the highest CAGR, and why?

By Region North America

Europe

China

India

Japan

+91-8087042414 (Asia) | (+1) 646 781 7170 (Int'l) | help@grandresearchstore.com

Heart Failure Drug Forecast and Marke tIndustry - Riding on Regulatory and Cha nge in Consumer Preferences

Get in touch Call:

Download Free Sample

+91-8087042414 (Asia) (+1) 646 781 7170 (Int'l) E-mail: help@grandresearchstore.com

Sample includes 

Table Of Contents



List of Tables & Figures



Charts



Research Methodology